Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
|Videos|July 2, 2021
Urology Malpractice: What is the role of an expert witness in litigation?
Author(s)Urology Times staff
Advertisement
In this interview, Kenton H. Steele Esq, discusses what is required for someone to serve as an expert witness. Steele is an attorney in the Columbus, Ohio office of Reminger Co., LPA and specializes in malpractice defense and insurance litigation.
Advertisement
Related to this article
Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Advertisement
Advertisement
Trending on Urology Times
1
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
Talazoparib/enzalutamide approved for HRR-mutated mAPMN/S prostate cancer
4
Daniel Heng, MD, highlights final LITESPARK-011 results in advanced ccRCC
5